Trials / Not Yet Recruiting
Not Yet RecruitingNCT07476586
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants
A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biomarker Characteristics of a Single Subcutaneous Injection of GenSci161 Injection in Healthy Adult Participants
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To Evaluate the Safety and Tolerability, Pharmacokinetics and Biomarker of GenSci161 in a Randomized, Double-blind, Placebo-controlled Study in Healthy Adult Participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GenSci161 | Administered subcutaneous injection |
| DRUG | Placebo | Administered subcutaneous injection |
Timeline
- Start date
- 2026-04-23
- Primary completion
- 2027-05-06
- Completion
- 2027-08-10
- First posted
- 2026-03-17
- Last updated
- 2026-03-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07476586. Inclusion in this directory is not an endorsement.